EyePoint (EYPT) Change in Receivables (2011 - 2026)
EyePoint (EYPT) reported Change in Receivables of $5.0 million for Q1 2026, up 244.52% on a YoY basis from $1.4 million in Q1 2025, and down 54.05% sequentially from $10.8 million in Q4 2025.
EyePoint (EYPT) Change in Receivables (2011 - 2026) Analysis & Trends
EyePoint (EYPT) has 16 years of Change in Receivables data on file, last reported at $5.0 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables rose 244.52% year-over-year to $5.0 million; the trailing twelve-month figure through Mar 2026 stood at $19.0 million (up 355.9% YoY), and the FY2025 full-year result was $10.7 million, up 4271.72% from the prior year.
- Change in Receivables fell to $5.0 million in Q1 2026, from $10.8 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $10.8 million in Q4 2025 to a low of -$10.7 million in Q3 2023.
- A 5-year average of $240882.4 and a median of $269000.0 in 2023 frame the typical range for Change in Receivables.
- Across the five-year window, Change in Receivables plunged 2820.65% in 2023 and surged 678.69% in 2025, its largest moves.
- Tracing EYPT's Change in Receivables over 5 years: stood at -$6.3 million in 2022, then soared by 104.28% to $269000.0 in 2023, then tumbled by 792.57% to -$1.9 million in 2024, then surged by 678.69% to $10.8 million in 2025, then plunged by 54.05% to $5.0 million in 2026.
- Business Quant data shows EYPT's Change in Receivables at $5.0 million in Q1 2026, $10.8 million in Q4 2025, and $3.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | EyePoint | 358.61 Mn | 136.07 Mn | 168,000.00 | 4.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.95 Mn |
| Mar 31, 2026 | 4.95 Mn |
| Dec 31, 2025 | 10.78 Mn |
| Dec 31, 2025 | 10.78 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Jun 30, 2025 | 180,000.00 |
| Jun 30, 2025 | 180,000.00 |
| Mar 31, 2025 | -3.43 Mn |
| Mar 31, 2025 | -3.43 Mn |
| Dec 31, 2024 | -1.86 Mn |
| Dec 31, 2024 | -1.86 Mn |
| Sep 30, 2024 | 939,000.00 |
| Sep 30, 2024 | 939,000.00 |
| Jun 30, 2024 | -3.09 Mn |
| Jun 30, 2024 | -3.09 Mn |
| Mar 31, 2024 | 4.26 Mn |
| Mar 31, 2024 | 4.26 Mn |
| Dec 31, 2023 | 269,000.00 |
| Dec 31, 2023 | 269,000.00 |